Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof of Concept Study to Evaluate Treatments' Efficacy by Monitoring Minimal Residual Disease Using ctDNA in HR-positive/HER2-negative Early Breast Cancer Population

NCT05708235 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT05708235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05708235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof of Concept Study to Evaluate Treatments' Efficacy by Monitoring Minimal Residual Disease Using ctDNA in HR-positive/HER2-negative Early Breast Cancer Population
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 1, 2024
Completion date
June 30, 2028
Enrollment
976 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer